Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. per Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W